Comprehensive assessment of tumour budding on cytokeratin stains in colorectal cancer. by Rieger, Gregor et al.
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/his.13164 
This article is protected by copyright. All rights reserved. 
DR VIKTOR HENDRIK KOELZER (Orcid ID : 0000-0001-9206-4885) 
 
Received Date : 07-Dec-2016 
Revised Date   : 03-Jan-2017 
Accepted Date : 05-Jan-2017 
Article type      : Original Article 
 
Comprehensive assessment of tumour budding on cytokeratin stains in 
colorectal cancer. 
 
Gregor Rieger*a, Viktor H. Koelzer*a,b, Heather E. Dawsona, Martin D. Bergerc,d, Marion Hädriche, 
Daniel Inderbitzine,f, Alessandro Luglia, Inti Zlobeca  
 
a Institute of Pathology, University of Bern, Murtenstrasse 31, Bern, 3010, Switzerland 
b Institute of Pathology, Cantonal Hospital Baselland, Liestal, Mühlemattstrasse 11, 4410, 
Switzerland 
c Department of Medical Oncology, Bern University Hospital, Switzerland 
d Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of 
Medicine, University of Southern California, Los Angeles, CA, USA 
e Departments of Visceral Surgery and Medicine, Bern University Hospital, Bern, Switzerland 
f Department of Surgery, Bürgerspital Solothurn, Solothurn, Switzerland 
 
* Equally contributing first authors 
 
 
Short title: Tumour budding in colorectal cancer 
 
Corresponding author 
Prof. Inti Zlobec, PhD 
Institute of Pathology, University of Bern 
Murtenstr. 31, CH-3010 Bern, Switzerland 
Telephone: 0041-31-632-8755 
Fax: 0041-31-632-4995 
E-mail: inti.zlobec@pathology.unibe.ch 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Conflict of interest statement and funding disclosures: 
The authors have no relevant affiliations or financial involvement with any organization or entity 
with a financial interest in or financial conflict with the subject matter or materials discussed in the 
manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert 
testimony, royalties or patents received or pending.  
 
ABSTRACT  
Background: Tumour budding in colorectal cancer (CRC) is a recognized prognostic parameter. Aim 
of this study is to address the use of cytokeratin immunostaining for visualization and scoring of 
tumour buds. 
Methods: Ten hotspots (0.238 mm2) of peritumoural (PTB) and intratumoural (ITB) budding were 
evaluated in surgical resections from 215 patients. The budding counts in the 10 densest regions 
anywhere in the tumour were combined into an overall tumour budding (OTB) score. The PTB, ITB 
and OTB hotspot with the maximum budding count was then evaluated. Finally, continuous and cut-
off values of 10 buds/HPF (PTB10HPF), 5 buds/HPF (ITB10HPF) and 8 buds/HPF (OTB10HPF ) were used to 
categorize budding counts into low/high-grade scores. 
Results: All budding scores were highly correlated. PTB and ITB counts were associated with many 
clinicopathological features including tumour stage, lymph node and distant metastasis, venous and 
lymphovascular invasion and disease-free survival (DFS) (all p<0.05). Analyses of OTB counts 
recapitulated these associations, including a lower DFS with a greater number of tumour buds 
(p=0.0309; HR (95%CI): 1.032 (1.003-1.062)). One OTB hotspot performed similarly as ten OTB 
hotspots in terms of relationship with outcome. These statistical significances were largely lost when 
cut-offs were applied to PTB, ITB or OTB counts. 
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Conclusions: OTB count in a single hotspot on cytokeratin-stained CRC tissue sections is a fast and 
reliable prognostic scoring system for the assessment of tumour budding. This approach should be 
considered in future studies.  
Keywords: colorectal cancer; prognosis; pathology; precision medicine 
 
INTRODUCTION 
Single cancer cell invasion or collective migration of small tumour clusters in the stroma of colorectal 
carcinoma (CRC) is referred to as tumour budding 1. The presence of tumour buds at the invasion 
front (peritumoural budding, PTB) and in the tumour centre (intratumoural budding, ITB) is linked to 
an aggressive tumour phenotype with adverse clinicopathological features and poorer survival of 
CRC patients 2-6. Quantification of tumour buds has major potential for clinical management: First, 
enumeration of tumour buds may improve the risk stratification of patients with endoscopically 
resected CRC and can aid the decision for colorectal surgery 6-10. Second, assessment of tumour 
budding may allow the identification of high risk stage II CRC patients for intensified follow up and 
adjuvant therapy trials 2, 4, 11. Last, detection of tumour buds in pre-operative biopsies may indicate 
an increased risk of nodal metastases and resistance to neoadjuvant therapy in rectal cancer 
patients 12, 13. 
Recently, an international panel of experts recommended guidelines for the assessment of tumour 
budding and outlined several areas that would benefit from a higher level of evidence in future 
studies 14. In particular, the role of cytokeratin staining, its corresponding scoring system (counts 
versus low/high-grade categories and number of fields) as well as the location within the tumour 
(intra- or peri-tumoural budding) were outlined as critical areas for further pursuit.  
In this study, we perform a comprehensive methodological assessment of tumour budding on 
cytokeratin stained sections in order to answer questions regarding: optimal tumour location for 
scoring, the use of continuous/categorical scoring approaches and the number of fields.  
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PATIENTS AND METHODS 
A sample size calculation was performed in order to determine the number of patients for inclusion 
in this retrospective cohort. Using lymph node status as outcome, and high-/low-grade budding as 
predictor, n=160 patients of all stages were required to reach 80% power, and an effect size of 
OR=2.8. Two-hundred and fifteen non-consecutive primary CRC patients could be included. These 
patients were treated between 2002 and 2011 at the Bern University Hospital, Switzerland. 
Histopathological H&E slides were re-reviewed (AL, HD, VHK) according to the UICC TNM 7th edition 
15. Patient characteristics are summarized in Table S1 and include information on gender, age, 
histological subtype (adenocarcinoma, mucinous, other), tumour location, pathological tumour (pT) 
and nodal stage (pN), presence of distant metastasis as determined by clinical and radiographic 
examination (cM), data on lymphatic (L), venous (V) and perineural invasion (Pn), tumour grade (G), 
resection status (R), tumour border configuration as percentage of pushing growth pattern (TBC), 
tumour deposits, pre- and postoperative therapy (Preop Tx; Postop Tx). Microsatellite instability 
status (MSI) was determined using a panel of three Bethesda markers (BAT25, BAT26 and D2S123) as 
previously described 16. Tumours were classified as MSI+ if they had two or more unstable markers 
and MSI– if all markers were stable. One tumour showing one single unstable marker was not 
classified. Clinical and survival information was retrieved from patient records. Mean and median 
follow up were 44 and 32 months, respectively (min and max: 1-142 months). No patients were 
treated by endoscopic tumour resection or neoadjuvant chemotherapy. Patients were followed up 
in accordance with the recommendations of the Swiss Society of Gastroenterology for surgically 
resected colorectal tumours 17. This includes serial clinical examinations and evaluation of 
carcinoembryonic antigen (CEA) serum levels, a colonoscopy at 12 and 48 months and yearly 
computed tomography (CT) scans of the thorax and abdomen for patients with pT3/4 disease 
following resection. For rectal cancer patients, rectal endosonography or pelvic magnetic resonance 
imaging (MRI) is performed at 6-monthly intervals for the first 2 years followed by yearly CT scans of 
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the thorax, abdomen and pelvis. A lower gastrointestinal endoscopy is performed at 6, 18 and 24 
months. 
 
Assay methods 
Specimens were fixed in 10% neutral buffered formalin. Gross assessment, dissection and sampling 
was performed in accordance with standard protocols. All diagnostic slides were re-reviewed and 
the tumour block with the highest budding grade on standard H&E histology was selected for 
cytokeratin immunohistochemistry (AE1/AE3; Dako, mouse monoclonal, 1:200, enzyme pre-
treatment 5 minutes, DAB chromogen; using a Leica Bond III instrument). Double-staining with CD8+ 
was performed but was not evaluated for this study. 
Assessment of tumour budding 
Tumour budding was defined as single tumour cells or tumour-cell-clusters of up to 5 cells (≤5 cells) 
in the tumour stroma of the invasive front (PTB) or within the tumour (ITB) in keeping with 
previously published definitions 3, 6, 18. Specifically, tumour budding cells were required to show 
cytoplasmic positivity and a nucleus in cytokeratin stains. To classify as ITB, tumor buds had to be 
surrounded by malignant glands on all sides. To classify as PTB, tumor buds had to be localized in the 
tumor stroma ahead of the invasive front. 
Tumour budding was assessed by one observer (GR) trained and supported by a team of expert 
gastrointestinal pathologists. Slides were first viewed at low-power to identify the densest areas of 
PTB and ITB. Tumour buds were counted in this area in one HPF (Nikon Eclipse 50i, 40x objective, 
field diameter 0.55mm, area 0.238mm2) which was labeled as the hotspot of tumour budding 
(PTBhotspot, ITBhotspot). A total of 10HPF in each area were evaluated for PTB10HPF and ITB10HPF. Overall 
tumour budding scores were defined as the hotspot with the highest score (OTBhotspot) and the 10 
HPF with the highest budding counts (OTB10HPF). The study design is shown in Figure 1. All observers 
were blinded to clinicopathological data. 
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Statistics 
Disease-free survival (DFS) was defined as the time from surgical resection to recurrence or death, 
whichever occurred first, with recurrence defined only by the reappearance of the primary CRC. 
Descriptive statistics were performed for all budding counts. Pearson’s correlation coefficient was 
used to determine the strength of the linear relationship (r). The association of tumour budding as a 
continuous variable with categorical endpoints was analysed with the Wilcoxon Rank Sum Test and 
with logistic regression. Previously published cut-offs of 10 buds for the PTB10HPF 
19 and 5 buds for the 
ITB10HPF 
20 method were used. For OTB, receiver operating characteristic (ROC) derived thresholds 
were investigated using death as an endpoint. The Kaplan-Meier method was used to represent 
survival curves and the log-rank test was used to test significant survival time differences. The Chi-
Square or Fisher’s Exact tests were used where appropriate. Analyses were performed using SPSS 
(Version 21) and with SAS (Version 9.4 SAS Institute, Cary, NC). P-values <0.05 were considered 
statistically significant. 
Ethics approval 
The use of patient material was approved by the ethics commission of the canton of Bern (KEK-
200/14). 
 
RESULTS 
Tumour budding was assessed in 1 hotspot or in 10 hotspots containing the densest regions of 
tumour buds in three different locations: ITB, PTB, or independently of location using an OTB count 
(Figure 2).  
Topographic assessment of tumour budding in CRC 
Descriptive statistics for PTB, ITB and OTB are found in Table 1. The mean number of PTB counts 
across 10 HPFs was 8.5 in comparison to 7.6 and 8.0 for ITB and OTB. For the single hotspot, OTB 
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counts were largest with 15.8 buds/HPF, followed by PTB (13.8 buds/HPF) and ITB (11.8 buds/HPF). 
All values of PTB, ITB and OTB correlated significantly with each other (Table 2). 
Tumour budding and association with clinicopathological features 
Continuous scores 
Tumour budding counts in any location were not correlated with gender, age, resection margin 
status or MSI status. Table 3 highlights the associations between PTB, ITB and OTB and other 
clinicopathological features. Tumour budding counts were significantly associated (p<0.05, all) with 
more advanced T-stage, presence of nodal metastasis, lymphatic invasion, venous invasion, tumour 
grade, perineural invasion and infiltrating tumour border configuration independent of the location 
of assessment (PTB, ITB or OTB, hotspot or 10HPF).  
DFS times were available for 208 patients with 38 patients relapsing during clinical follow-up. 
Significant associations of tumour budding counts with a shorter DFS as assessed by PTB10HPF 
(p=0.0315; HR (95%CI): 1.028 (1.002-1.053)), ITBhotspot (p=0.0126; HR (95%CI): 1.028 (1.006-1.051)), 
OTB10HPF (p=0.0309; HR (95%CI): 1.032 (1.003-1.062)) and OTBhotspot (p=0.05; HR (95%CI): 1.021 (1.0-
1.042)) were identified. 
Cut-off scores 
In order to determine the impact of cut-off scores on the association of budding with 
clinicopathological features, we applied a threshold of 10 buds for PTB counts19, 5 buds for ITB 
counts 20 and newly identified thresholds of 8 and 14 for OTB10HPF and OTBhotspot. Frequencies of high-
grade budding for PTB, ITB and OTB are found in Table S2. 
Table 3 highlights loss of associations when budding scores are dichotomized. Only presence of 
nodal metastasis and infiltrating tumour border configuration (all p<0.05) were reliably predicted by 
classification according to cut-off scores. Inconsistent associations were also identified between high 
grade budding cancers and clinical evidence of distant metastasis. Importantly, no associations of 
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tumour budding as assessed by cut-off scores with DFS were identified (PTB10HPF p=0.6681; ITB10HPF 
p=0.7198, OTB10HPF p=0.7831, PTBhotspot p=0.8864, ITBhotspot p=0.5243, OTBhotspot p=0.4534). 
 
DISCUSSION 
The International Tumour Budding Consensus Conference (ITBCC) in April 2016 gathered experts 
from around the world to discuss the issues related to tumour budding 14. One major area of interest 
was the use of cytokeratin stains for scoring. It was outlined that the evidence supporting the 
implementation of cytokeratin staining was moderate to low and was an area requiring further work 
in future studies. We undertook this study to confirm the utility of cytokeratin staining for the 
evaluation of tumour budding. 
Evidence from the literature suggests that both PTB in surgical resections and ITB in preoperative 
biopsies is not only predictive of lymph node and distant metastasis but also of poorer overall and 
disease-free survival 3, 6. However, what qualifies as PTB and ITB in resection specimens is not always 
clear and borders between PTB and ITB are often blurred. In a first step, we scored ten clearly 
defined regions of PTB and ITB which were then used to calculate an overall tumour budding score 
(OTB) to determine the impact of the location of scoring on clinicopathological endpoints. All values 
of budding are highly correlated with each other. Moreover, we show that the associations 
identified from PTB and ITB are recapitulated in OTB, suggesting that as long as the densest region of 
tumour budding is identified, the location (PTB or ITB) does not actually play a role. 
Scoring systems for tumour budding include both subjective and more quantitative methods, and 
often only a single field of view is considered 5, 21, 22. Previous studies on PTB demonstrate that the 
evaluation of 1 or 10 hotspots on cytokeratin produces nearly identical results in terms of inter-
observer agreement, although with a slight advantage for PTB counted in multiple regions 23. In this 
study, we show that the evaluation of a single OTB hotspot performs similarly to the evaluation of 10 
OTB regions, suggesting that only one densest region of tumour budding scored anywhere 
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throughout the tumour would be sufficient. Several arbitrary cut-offs ranging from single cells to 
small clusters of ≤4 or ≤5 have been used for the definition of a single tumour bud (see 3, 18 for 
critical discussion). A consistent adverse prognostic impact of tumour budding has been observed in 
studies using either value 18.  However, a systematic comparison is so far lacking in the literature and 
needs to be addressed in future investigations.  
 
Another central issue is the use of tumour budding counts or a low/high-grade scoring approach, 
determined around a cut-off 3, 6. The distribution of tumour budding counts points to no obvious cut-
off that would separate this cohort of patients. Additionally, the ROC curve for tumour budding and 
lymph node metastasis (or any other endpoint with clinical relevance) presents no evident cut-off 
point to best discriminate between outcomes. Several more arguments supporting a continuous 
count of tumour buds can be made: a larger number of tumour buds can potentially have a clinically 
relevant meaning- we have previously shown this in the context of intratumoural budding in rectal 
tumour biopsies with the aim of predicting lymph node and distant metastasis 20 Tumors with 9 or 
11 buds cannot be so biologically different that they warrant being placed into low and high-grade 
categories using a cut-off of 10 buds. In this study, we show that the associations of tumour budding 
with a range of different clinicopathological features, and most importantly with DFS, are only 
achieved with continuous scores. Based on these arguments, we reason that the number of tumour 
buds on cytokeratin stains should be recorded, even if these counts are used in a categorical scoring 
system in a second step. 
This study specifically focuses on cytokeratin staining for the evaluation of tumour budding cells. We 
used AE1/AE3 cytokeratin staining based on previous studies 19, 20, 24. AE1/AE3 is a keratin cocktail 
that detects cytokeratin 1-6, 8, 10, 14-16 and 19, but does not detect CK17 or CK18 25. The choice of 
a broad-spectrum anti-cytokeratin is of central importance, as some molecular subgroups of CRC 
may express a differential cytokine profile. In particular, MSI+ CRC may show a loss of cytokeratin 20 
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and aberrant expression of cytokeratin 7 26. Further, some CRC with neuroendocrine differentiation 
may show only a focal or dotlike expression of cytokeratin at the invasive front, making a careful 
interpretation mandatory 27. 
To conclude, this study demonstrates that an OTB count in a single hotspot on cytokeratin-stained 
CRC tissue sections excels in the assessment of tumour budding. Although further studies are 
needed to validate these findings, a count of OTB encompasses the positive aspects of PTB and ITB 
and therefore will be applicable to both surgical resections and preoperative biopsies. 
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FIGURE LEGENDS 
Figure 1: Study Design. 
Figure 2: Scoring method for topographic assessment of tumour budding showing peritumoral (PTB), 
intratumoral (ITB) and overall tumor budding (OTB) evaluation. 
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Table 1: Descriptive statistics for PTB, ITB and OTB (n=215) 
 
Budding PTB10HPF ITB10HPF OTB10HPF PTBhotspot ITBhotspot OTBhotspot 
Mean 8.5 7.6 8.0 13.8 11.8 15.8 
Median 6 4.8 5.5 10 8.0 12 
Min 0 0 0 0 0 0 
Max 85 67 64.5 96 82 96 
 
 
Table 2: Correlation coefficients (r) underling the linear relationships between PTB, ITB and OTB 
(n=215) 
 
 PTB10HPF ITB10HPF OTB10HPF PTBhotspot ITBhotspot OTBhotspot 
PTB10HPF 1.0      
ITB10HPF 0.81 1.0     
OTB10HPF 0.95 0.95 1.0    
PTBhotspot 0.93 0.74 0.88 1.0   
ITBhotspot 0.83 0.93 0.93 0.77 1.0  
OTBhotspot 0.91 0.85 0.94 0.94 0.91 1.0 
*All correlations p<0.0001  
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Table 3: Association of PTB, ITB and OTB scores with clinicopathological features by continuous and cut-off scores (n=215; p-values are shown) 
Evaluation by continuous scores Evaluation by cut-off scores 
 PTB10HPF ITB10HPF OTB10HPF PTBhotspot ITBhotspot OTBhotspot  PTB10HPF ITB10HPF OTB10HPF PTBhotspot ITBhotspot OTBhotspot 
Gender 0.1804 0.1615 0.1224 0.2413 0.2871 0.0953  0.1025 0.064 0.0798 0.4492 0.8238 0.0879 
              
Histology 0.0006 0.0025 0.0011 0.0013 0.0019 0.1137  0.0017 0.0953 0.011 0.0172 0.0629 0.1769 
              
Location 0.0744 0.1248 0.0652 0.1564 0.05 0.04  0.0438 0.4003 0.0545 0.1411 0.5509 0.0607 
              
pT 0.0004 <0.0001 <0.0001 0.0058 0.0015 0.0022  0.0354 0.0017 0.0028 0.0357 0.0001 0.0837 
              
pN 0.0004 <0.0001 <0.0001 0.0015 0.0001 0.0002  0.0034 0.0001 0.0009 0.0127 0.0004 0.0011 
              
cM 0.0117 <0.0001 0.0006 0.2554 0.0006 0.0414  0.2131 0.0004 0.0028 0.6364 0.0008 0.1932 
              
L <0.0001 <0.0001 <0.0001 0.0001 0.0004 <0.0001  0.082 <0.0001 0.0013 0.0001 0.0001 0.0044 
              
V 0.0013 0.0015 0.0005 0.0029 0.0136 0.0019  0.2273 0.192 0.0041 0.0011 0.1456 0.0048 
              
Pn 0.0104 0.0003 0.002 0.0197 0.0107 0.0234  0.155 0.0219 0.0251 0.0846 0.0393 0.1162 
              
G 0.0115 0.0002 0.0012 0.0304 0.001 0.0046  0.0024 0.0118 0.0017 0.2442 0.0462 0.1084 
              
TBC <0.0001 0.0002 0.0063 <0.0001 0.0013 0.0003  0.0291 <0.0001 0.0016 0.0278 0.0005 0.0179 
              
Post TX 0.0006 <0.0001 0.0001 0.0011 0.0004 0.0002  0.0009 0.0002 0.0007 0.0743 0.0059 0.201 
              
MSI 0.6399 0.1533 0.3068 0.9253 0.1577 0.4818  0.4427 0.6337 0.8336 0.7724 0.6003 0.9385 
              
DFS 0.0315 0.0632 0.0309 0.1112 0.0126 0.05  0.6681 0.7198 0.7831 0.8864 0.5243 0.4534 
HR (95%CI) 1.028 
(1.002-
1.053) 
1.029 
(0.998-
1.06) 
1.032 
(1.003-
1.062) 
1.018 
(0.996-
1.041) 
1.028 
(1.006-
1.051) 
1.021     
(1.000-
1.042) 
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